Granulocyte colony-stimulating factor in patients with acute ischemic stroke results of the AX200 for ischemic stroke trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F13%3AE0103703" target="_blank" >RIV/00843989:_____/13:E0103703 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/13:A1401AZE RIV/61989592:15120/13:33149366

Výsledek na webu

<a href="http://dx.doi.org/10.1161/STROKEAHA.113.001531" target="_blank" >http://dx.doi.org/10.1161/STROKEAHA.113.001531</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1161/STROKEAHA.113.001531" target="_blank" >10.1161/STROKEAHA.113.001531</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Granulocyte colony-stimulating factor in patients with acute ischemic stroke results of the AX200 for ischemic stroke trial

Popis výsledku v původním jazyce

Background and Purpose: Granulocyte colony-stimulating factor (G-CSF; AX200; Filgrastim) is a stroke drug candidate with excellent preclinical evidence for efficacy. A previous phase IIa dose-escalation study suggested potential efficacy in humans. The present large phase IIb trial was powered to detect clinical efficacy in acute ischemic stroke patients. Methods: G-CSF (135 mu g/kg body weight intravenous over 72 hours) was tested against placebo in 328 patients in a multinational, multicenter, randomized, and placebo-controlled trial (NCT00927836; www.clinicaltrial.gov). Main inclusion criteria were 9-hour time window after stroke onset, infarct localization in the middle cerebral artery territory, baseline National Institutes of Health Stroke Scalescore range of 6 to 22, and baseline diffusion-weighted imaging lesion size 15 mL. Primary and secondary end points were the modified Rankin scale score and the National Institutes of Health Stroke Scale score at day 90, respectively. Dat

Název v anglickém jazyce

Granulocyte colony-stimulating factor in patients with acute ischemic stroke results of the AX200 for ischemic stroke trial

Popis výsledku anglicky

Background and Purpose: Granulocyte colony-stimulating factor (G-CSF; AX200; Filgrastim) is a stroke drug candidate with excellent preclinical evidence for efficacy. A previous phase IIa dose-escalation study suggested potential efficacy in humans. The present large phase IIb trial was powered to detect clinical efficacy in acute ischemic stroke patients. Methods: G-CSF (135 mu g/kg body weight intravenous over 72 hours) was tested against placebo in 328 patients in a multinational, multicenter, randomized, and placebo-controlled trial (NCT00927836; www.clinicaltrial.gov). Main inclusion criteria were 9-hour time window after stroke onset, infarct localization in the middle cerebral artery territory, baseline National Institutes of Health Stroke Scalescore range of 6 to 22, and baseline diffusion-weighted imaging lesion size 15 mL. Primary and secondary end points were the modified Rankin scale score and the National Institutes of Health Stroke Scale score at day 90, respectively. Dat

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Stroke

ISSN

0039-2499

e-ISSN

—

Svazek periodika

44

Číslo periodika v rámci svazku

n. 10

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

"p. 2681-2687"

Kód UT WoS článku

000324831900018

EID výsledku v databázi Scopus

—